drugset / Trial / NCT01173874

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

NCT01173874

Phase 3 Completed 120 enrolled New York State Psychiatric Institute
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score and Cognitive Assessment Interview).

Timeline

Start
2010-07
Primary completion
2013-10
Completion
2013-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule

Indications